Thrombosis, platelets, microparticles and PAH: more than a clot

Lannan KL; Phipps RP; White RJ

doi:10.1016/j.drudis.2014.04.001

Thrombosis, platelets, microparticles and PAH: more than a clot

Lannan KL, Phipps RP, White RJ2014Drug Discovery TodayReview

10.1016/j.drudis.2014.04.001 PubMed

Cardiovascular

Abstract

Pulmonary arterial hypertension (PAH) is a progressive disease that involves pathological remodeling, vasoconstriction and thrombosis. Alterations in hemostasis, coagulation and platelet activation are consistently observed in PAH patients. Microparticles derived from platelets, inflammatory cells and the endothelium are an increasingly well-recognized signal in a variety of cardiovascular diseases, including PAH. This review will focus on the roles of coagulation, thrombosis, platelet activation and microparticles in the pathology and progression of PAH.

Part of CIRS Nexus · Curated by Lauren Lowenstein, The Biotoxin Lady

Key Biomarkers

coagulationhemostasisMicroparticlesPlatelets

Symptom Clusters

pathological remodelingthrombosisvasoconstriction

References (3)

Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated plateletsThrombosis and Haemostasis · 2007
On the origin of microparticles: From “platelet dust” to mediators of intercellular communicationPulmonary Circulation · 2013
Platelet indices in patients with pulmonary arterial hypertensionClin Appl Thromb Hemost · 2011